Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Abstract Text:

OBJECTIVES: Hereditary medullary thyroid carcinoma (MTC) is caused by germ-line mutations in the RET proto-oncogene. Our study addresses the difference in development of MTC between rare mutations in RET codons 790, 791 and 804. DESIGN: We evaluated tumour stage, calcitonin levels, biochemical cure rates and associated endocrinopathies in 153 German/Austrian patients with RET 790 (n = 47), 791 (n = 56) and 804 mutations (n = 50), divided into index- and screening groups. RESULTS: Age at diagnosis in index-patients did not differ significantly among the three codon groups (medians of 57, 61 and 53 years). Tumour stage at diagnosis was significantly less advanced with codon 791 (n = 22) than 790 (n = 16) and 804 (n = 16) mutations (P = 0.001). In screening patients, age at diagnosis did not differ significantly among the three groups (medians 19, 24 and 32 years). Tumour stage at diagnosis was also significantly less advanced with codon 791 (n = 34) than 790 (n = 31) and 804 (n = 34) (P = 0.032). Preoperative basal calcitonin levels were significantly lower in codon 791 carriers compared to codon 790 carriers, and cure rates were significantly higher in both index (75%vs. 31%; P = 0.03) and screening patients (100%vs. 75%; P = 0.015). Additional endocrinopathies were observed only with codon 791 carriers (four pheochromocytomas and two hyperparathyroidism). CONCLUSION: There is a significant difference in MTC development with less extensive C-cell disease, higher cure rate and more frequent additional endocrinopathies in carriers of RET codon 791 mutations compared with carriers of codons 790 and 804 mutations. This information should be considered when age of prophylactic thyroidectomy is discussed.

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical endocrinology

VOLUME: 69

Page Numbers: 259-63

Journal Abbreviation: Clin. Endocrinol. (Oxf)

ISSN: 1365-2265

DAY: 3

MONTH: 02

YEAR: 2008

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 346653

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.

AFFILIATION: Endocrine Practice, Molecular Laboratory, Heidelberg, Germany. karin.frankraue@raue-endokrinologie.de

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Endocrinol (Oxf)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791 Related Publications

• Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
• Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.
• Endocrine aspects of medullary thyroid carcinoma.
• Epidemiological aspects of hypercalcemia of malignancy.
• Epidemiology of medullary thyroid carcinoma.
• Postsurgical follow-up and management.
• Rapid detection of pigeon herpesvirus, fowl adenovirus and pigeon circovirus in young racing pigeons by multiplex PCR.
• Screening for MEN 2 with biochemical and genetic markers.
• [Therapy of lacrimal duct diseases.]